Disappointing news for the Huntington’s disease community from Novartis Pharmaceutical Company regarding stopping the clinical trial VIBRANT-HD. Read full article here
“Tucked into its latest earnings report, Novartis confirmed to investors that it has stopped developing an experimental drug for Huntington’s disease.
The reason, according to Novartis, was an “overall assessment of the risk-benefit profile”
Register for Webinar on February 22, 2023
No Comments